

Brain Omega-3 Program
- In this program, we study mechanisms of how to prevent APOE4 genotype from increasing the risk of Alzheimer’s disease or vascular dementia using animal studies, brain imaging and clinical trials by focusing on fatty acid brain metabolism and neuroinflammation.
- These are the fundamental questions our lab is trying to answer:
- Can high dose omega-3 slow down cognitive decline in younger cognitively healthy APOE4 carriers before the onset of dementia?
- Can inhibition of cPLA2 offset neuroinflammation in APOE4 carriers with prodromal Alzheimer’s disease?
- Can we develop imaging biomarkers of omega-3 and omega-6 fatty acid uptake to guide the response of the diet and cPLA2 inhibition?
Brain Omega-3 Program

APOE4 and brain inflammation in the Religious Order Study
Why would APOE4 carriers with dementia not benefit from omega-3 supplementation? In this work, Brandon Ebright led our team in collaboration with RUSH Medical Center

New Inflammation PET probe
Over the past 4 years, Juno Van Valkenburg and Marlon Duro synthesized 18-F Arachidonic Acid (AA) to image brain lipid inflammation in mice models of

APOE4 and Brain Inflammation
As you probably know, there are no effective treatments that can modify or slow down the progression of Alzheimer’s Disease. It is necessary to have

Brain DHA Delivery
A small clinical trial from USC provides important clues about this discrepancy, in the first Alzheimer’s prevention study to compare levels of omega-3s in the
Articles

Presentation
Miscellaneous

APOE4 and brain inflammation in the Religious Order Study
Why would APOE4 carriers with dementia not benefit from omega-3 supplementation? In this work, Brandon Ebright led our team in collaboration with RUSH Medical Center

New Inflammation PET probe
Over the past 4 years, Juno Van Valkenburg and Marlon Duro synthesized 18-F Arachidonic Acid (AA) to image brain lipid inflammation in mice models of